New York State Common Retirement Fund Decreases Position in argenx SE (NASDAQ:ARGX)

New York State Common Retirement Fund lessened its holdings in shares of argenx SE (NASDAQ:ARGX - Free Report) by 39.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 63,534 shares of the company's stock after selling 41,000 shares during the period. New York State Common Retirement Fund owned 0.11% of argenx worth $39,073,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Venturi Wealth Management LLC purchased a new stake in argenx in the 4th quarter valued at approximately $66,000. Nkcfo LLC purchased a new position in shares of argenx in the 4th quarter valued at $68,000. Advisors Preferred LLC acquired a new stake in argenx during the 4th quarter valued at $73,000. Cromwell Holdings LLC grew its holdings in argenx by 73.3% during the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company's stock worth $85,000 after acquiring an additional 66 shares in the last quarter. Finally, GAMMA Investing LLC grew its position in shares of argenx by 44.8% during the 4th quarter. GAMMA Investing LLC now owns 252 shares of the company's stock valued at $155,000 after buying an additional 78 shares during the last quarter. 60.32% of the stock is owned by institutional investors and hedge funds.

argenx Trading Down 0.5 %

Shares of ARGX traded down $3.01 on Friday, reaching $644.48. 215,707 shares of the company's stock traded hands, compared to its average volume of 262,044. argenx SE has a 52-week low of $349.86 and a 52-week high of $678.21. The stock has a market cap of $39.16 billion, a PE ratio of -732.36 and a beta of 0.58. The stock's 50 day simple moving average is $642.31 and its two-hundred day simple moving average is $585.45.

Analyst Upgrades and Downgrades

ARGX has been the subject of a number of recent analyst reports. Wolfe Research raised shares of argenx from a "peer perform" rating to an "outperform" rating and set a $697.00 price objective for the company in a research note on Tuesday, November 12th. JPMorgan Chase & Co. upped their target price on shares of argenx from $640.00 to $670.00 and gave the company an "overweight" rating in a research note on Monday, November 4th. Piper Sandler upped their price target on argenx from $620.00 to $725.00 and gave the company an "overweight" rating in a research report on Tuesday, January 7th. Baird R W lowered shares of argenx from a "strong-buy" rating to a "hold" rating in a research report on Friday, November 1st. Finally, Wells Fargo & Company boosted their price objective on argenx from $639.00 to $723.00 and gave the stock an "overweight" rating in a research note on Thursday, December 19th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $658.39.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.